Liraglutide and Renal Outcomes in Type 2 Diabetes

By J. Mann, D. Ørsted, K. Brown-Frandsen, S. Marso, N. Poulter, S. Rasmussen, K. Tornøe, B. Zinman, John B. Buse. New England Journal of Medicine, 2017

656 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Nephrology, Surgery

View Paper: https://www.semanticscholar.org/paper/e3932087f500b455476965939bdced15360eb028

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. J. Meier
2. M. Nauck
3. Nur Samsu

In Nephrology

1. Nur Samsu

In Surgery

1. J. Meier
2. M. Nauck

Citations in the corpus

• An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines (2020, background): “92), but this was almost entirely driven by a lower incidence of severe (A3) albuminuria.(88) Dulaglutide has also been shown to result in fewer”
• GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art (2020, background): “The discovery of beneficial renal effects using GLP-1 RAs is a recent achievement mainly based on the observations that GLP-1 RAs prevented new-onset macroalbuminuria [99,164,165], reduced urinary albumin excretion [164,165], or slowed the decline in the estimated glomerular filtration rate (eGFR) o”